Animal model of fetal and neonatal immune thrombocytopenia: Role of neonatal Fc receptor in the pathogenesis and therapy

Blood

Volumn 116, Issue 18, 2010, Pages 3660-3668

  Chen, Pingguo ^a,b   Li, Conglei ^b,c   Lang, Sean ^b,c   Zhu, Guangheng ^b   Reheman, Adili ^b   Spring, Christopher M ^b   Freedman, John ^b,c   Ni, Heyu ^a,b,c  

^a CANADIAN BLOOD SERVICES   (Canada)

^b ST MICHAEL'S HOSPITAL   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BETA3 INTEGRIN; FC RECEPTOR; IMMUNOGLOBULIN G;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; DOWN REGULATION; FEMALE; FETUS; HOMEOSTASIS; MALE; MOUSE; NEONATAL ALLOIMMUNE THROMBOCYTOPENIA; NEWBORN; NONHUMAN; PATHOGENESIS; PLACENTAL TRANSFER; PRIORITY JOURNAL; THROMBOCYTE;

EID: 78149300934     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2010-05-284919     Document Type: Article

References (49)

1. Bussel JB, Zabusky MR, Berkowitz RL, McFarland JG. Fetal alloimmune thrombocytopenia. N Engl J Med. 1997;337(1):22-26.
2. Newman PJ. Nomenclature of human platelet alloantigens: a problem with the HPA system? Blood. 1994;83(6):1447-1451.
3. Metcalfe P, Watkins NA, Ouwehand WH, et al. Nomenclature of human platelet antigens. Vox Sang. 2003;85(3):240-245.
4. Dreyfus M, Kaplan C, Verdy E, Schlegel N, Durand-Zaleski I, Tchernia G. Frequency of immune thrombocytopenia in newborns: a prospective study. Immune Thrombocytopenia Working Group. Blood. 1997;89(12):4402-4406.
5. Williamson LM, Hackett G, Rennie J, et al. The natural history of fetomaternal alloimmunization to the platelet-specific antigen HPA-1a (PlA1, Zwa) as determined by antenatal screening. Blood. 1998;92(7):2280-2287. (Pubitemid 28452968)
6. Turner ML, Bessos H, Fagge T, et al. Prospective epidemiologic study of the outcome and cost-effectiveness of antenatal screening to detect neonatal alloimmune thrombocytopenia due to anti-HPA-1a. Transfusion. 2005;45(12):1945-1956.
7. Kjeldsen-Kragh J, Killie MK, Tomter G, et al. A screening and intervention program aimed to reduce mortality and serious morbidity associated with severe neonatal alloimmune thrombocytopenia. Blood. 2007;110(3):833-839.
8. Reznikoff-Etievant MF. Management of alloimmune neonatal and antenatal thrombocytopenia. Vox Sang. 1988;55(4):193-201.
9. Mueller-Eckhardt C, Kiefel V, Grubert A, et al. 348 cases of suspected neonatal alloimmune thrombocytopenia. Lancet. 1989;1(8634):363-366. (Pubitemid 19103082)
10. Kaplan C, Morel-Kopp MC, Clemenceau S, Daffos F, Forestier F, Tchernia G. Fetal and neonatal alloimmune thrombocytopenia: current trends in diagnosis and therapy. Transfus Med. 1992;2(4):265-271.
11. Bussel JB, Skupski DW, MacFarland JG. Fetal alloimmune thrombocytopenia: consensus and controversy. J Matern Fetal Med. 1996;5(5):281-292. (Pubitemid 126717049)
12. Kornfeld I, Wilson RD, Ballem P, Wittmann BK, Farquharson DF. Antenatal invasive and noninvasive management of alloimmune thrombocytopenia. Fetal Diagn Ther. 1996;11(3):210-217.
13. Ghevaert C, Campbell K, Walton J, et al. Management and outcome of 200 cases of fetomaternal alloimmune thrombocytopenia. Transfusion. 2007;47(5):901-910.
14. Kaplan C, Daffos F, Forestier F, et al. Management of alloimmune thrombocytopenia: antenatal diagnosis and in utero transfusion of maternal platelets. Blood. 1988;72(1):340-343.
15. Davoren A, McParland P, Barnes CA, Murphy WG. Neonatal alloimmune thrombocytopenia in the Irish population: a discrepancy between observed and expected cases. J Clin Pathol. 2002;55(4):289-292.
16. Kanhai HH, Porcelijn L, Engelfriet CP, et al. Management of alloimmune thrombocytopenia. Vox Sang. 2007;93(4):370-385.
17. Jones EA. Immunoglobulins and the gut. Gut. 1972;13(10):825-835.
18. Simister NE, Mostov KE. An Fc receptor structurally related to MHC class I antigens. Nature. 1989;337(6203):184-187.
19. FWR Brambell. Nature. 1970;228(5272):694.
20. Rodewald R, Abrahamson DR. Receptor-mediated transport of IgG across the intestinal epithelium of the neonatal rat. Ciba Found Symp. 1982;(92):209-232.
21. Vaughn DE, Bjorkman PJ. Structural basis of pH-dependent antibody binding by the neonatal Fc receptor. Structure. 1998;6(1):63-73.
22. Raghavan M, Bonagura VR, Morrison SL, Bjorkman PJ. Analysis of the pH dependence of the neonatal Fc receptor/immunoglobulin G interaction using antibody and receptor variants. Biochemistry. 1995;34(45):14649-14657.
23. Rodewald R, Kraehenbuhl JP. Receptor-mediated transport of IgG. J Cell Biol. 1984;99(1 Pt 2):159s-164s.
24. Ghetie V, Popov S, Borvak J, et al. Increasing the serum persistence of an IgG fragment by random mutagenesis. Nat Biotechnol. Jul;15(7):637-640.
25. Ward ES, Zhou J, Ghetie V, Ober RJ. Evidence to support the cellular mechanism involved in serum IgG homeostasis in humans. Int Immunol. 2003;15(2):187-195.
26. Junghans RP, Anderson CL. The protection receptor for IgG catabolism is the beta2-microglobulin-containing neonatal intestinal transport receptor. Proc Natl Acad Sci U S A. 1996;93(11):5512-5516.
27. Roopenian DC, Christianson GJ, Sproule TJ, et al. The MHC class I-like IgG receptor controls perinatal IgG transport, IgG homeostasis, and fate of IgG-Fc-coupled drugs. J Immunol. 2003;170(7):3528-3533.
28. Li N, Zhao M, Hilario-Vargas J, et al. Complete FcRn dependence for intravenous Ig therapy in autoimmune skin blistering diseases. J Clin Invest. 2005;115(12):3440-3450.
29. Liu L, Garcia AM, Santoro H, et al. Amelioration of experimental autoimmune myasthenia gravis in rats by neonatal FcR blockade. J Immunol. 2007;178(8):5390-5398.
30. Akilesh S, Petkova S, Sproule TJ, Shaffer DJ, Christianson GJ, Roopenian D. The MHC class I-like Fc receptor promotes humorally mediated autoimmune disease. J Clin Invest. 2004;113(9):1328-1333.
31. Petkova SB, Akilesh S, Sproule TJ, et al. Enhanced half-life of genetically engineered human IgG1 antibodies in a humanized FcRn mouse model: potential application in humorally mediated autoimmune disease. Int Immunol. 2006;18(12):1759-1769.
32. Firan M, Bawdon R, Radu C, et al. The MHC class I-related receptor, FcRn, plays an essential role in the maternofetal transfer of gamma-globulin in humans. Int Immunol. 2001;13(8):993-1002.
33. Ni H, Chen P, Spring CM, et al. A novel murine model of fetal and neonatal alloimmune thrombocytopenia: response to intravenous IgG therapy. Blood. 2006;107(7):2976-2983.
34. Qiao SW, Kobayashi K, Johansen FE, et al. Dependence of antibody-mediated presentation of antigen on FcRn. Proc Natl Acad Sci U S A. 2008;105(27):9337- 9342.
35. Hodivala-Dilke KM, McHugh KP, Tsakiris DA, et al. beta3-integrin- deficient mice are a model for Glanzmann thrombasthenia showing placental defects and reduced survival. J Clin Invest. 1999;103(2):229-238.
36. Webster ML, Sayeh E, Crow M, et al. Relative efficacy of intravenous immunoglobulin G in ameliorating thrombocytopenia induced by antiplatelet GPIIbIIIa versus GPIbalpha antibodies. Blood. 2006;108(3):943-946.
37. Crow AR, Song S, Semple JW, Freedman J, Lazarus AH. IVIg inhibits reticuloendothelial system function and ameliorates murine passiveimmune thrombocytopenia independent of antiidiotype reactivity. Br J Haematol. 2001;115(3):679-686.
38. Kim J, Mohanty S, Ganesan LP, et al. FcRn in the yolk sac endoderm of mouse is required for IgG transport to fetus. J Immunol. 2009;182(5):2583-2589.
39. Althaus J, Weir EG, Askin F, Kickler TS, Blakemore K. Chronic villitis in untreated neonatal alloimmune thrombocytopenia: an etiology for severe early intrauterine growth restriction and the effect of intravenous immunoglobulin therapy. Am J Obstet Gynecol. 2005;193(3 Pt 2):1100-1104.
40. Roopenian DC, Akilesh S. FcRn: the neonatal Fc receptor comes of age. Nat Rev Immunol. 2007;7(9):715-725.
41. Ghetie V, Ward ES. Multiple roles for the major histocompatibility complex class I-related receptor FcRn. Annu Rev Immunol. 2000;18:739-766.
42. Kristoffersen EK. Human placental Fc gamma-binding proteins in the maternofetal transfer of IgG. APMIS Suppl. 1996;64:5-36.
43. Lin S, Sartori MJ, Mezzano L, de Fabro SP. Placental alkaline phosphatase (PLAP) enzyme activity and binding to IgG in Chagas' disease. Placenta. 2005;26(10):789-795.
44. Takizawa T, Anderson CL, Robinson JM. A novel Fc γ R-defined, IgG-containing organelle in placental endothelium. J Immunol. 2005;175(4):2331-2339.
45. Sachs UJ, Socher I, Braeunlich CG, Kroll H, Bein G, Santoso S. A variable number of tandem repeats polymorphism influences the transcriptional activity of the neonatal Fc receptor alpha-chain promoter. Immunology. 2006;119(1):83-89.
46. Hansen RJ, Balthasar JP. Intravenous immunoglobulin mediates an increase in anti-platelet antibody clearance via the FcRn receptor. Thromb Haemost. 2002;88(6):898-899.
47. Lazarus AH, Freedman J, Semple JW. Intravenous immunoglobulin and anti-D in idiopathic thrombocytopenic purpura (ITP): mechanisms of action. Transfus Sci. 1998;19(3):289-294.
48. Nimmerjahn F, Ravetch JV. Fcgamma receptors: old friends and new family members. Immunity. 2006;24(1):19-28.
49. Zhou J, Mateos F, Ober RJ, Ward ES. Conferring the binding properties of the mouse MHC class I-related receptor, FcRn, onto the human ortholog by sequential rounds of site-directed mutagenesis. J Mol Biol. 2005;345(5):1071- 1081. (Pubitemid 40092225)